Skip to main content
Log in

Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background. Researchers question whether estrogen receptorα-negative (ERN) and -positive (ERP) represent different stages of one disease or different breast cancer types.

Objective. To further examine ERα phenotypes, we stratified incident tumor characteristics in the Surveillance, Epidemiology, and End Results (SEER) Database (n = 82,488) by ERN and ERP.

Methods. Study variables included black–white race, age-at-diagnosis, and standard incident tumor characteristics. These characteristics were arbitrarily dichotomized into good versus poor prognostic factor groups, for example, good (tumor size ≤ 2.0 cm, negative axillary lymph nodes, and good histologic grade) versus poor (tumor size > 2.0 cm, positive nodes, and poor grade). Age frequency density plots were generated from the corresponding age-at-diagnosis frequency histograms. Average annual age-specific incidence rates (or risks) were adjusted to the 1970 United States standard female population.

Results. Age frequency density plots demonstrated bimodal premenopausal and postmenopausal breast cancer populations. ERN was correlated with premenopausal disease, black race, and poor prognostic factor groups, whereas ERP was associated with postmenopausal disease, white race, and favorable tumor characteristics. ERN rates increased premenopausally and then flattened to a nearly constant level after 50 years of age. ERP risk rose for most of a woman's lifetime with the greatest risk occurring between 75 and 79 years.

Conclusions. ERα exhibited bimodal age frequency distribution with a dichotomous pattern for age-specific rates, racial, and prognostic factor profiles. Menopause had a greater effect on ERN than ERP. Possible implications for breast carcinogenesis and cancer prevention are discussed in the text.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Henderson IC, Patek AJ: The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 52: 261–288, 1998

    Google Scholar 

  2. Easton D: Breast cancer – not just whether but when? [In Process Citation]. Nat Genet 26: 390–391, 2000

    Google Scholar 

  3. Hellman S: Natural history of small breast cancers. J Clin Oncol 12: 2229–2234, 1994

    Google Scholar 

  4. Moolgavkar SH, Day NE, Stevens RG: Two-stage model for carcinogenesis: epidemiology of breast cancer in females. J Natl Cancer Inst 65: 559–569, 1980

    Google Scholar 

  5. Tarone RE, Chu KC: The greater impact of menopause on El-phon Elt breast cancer incidence: a possible explanation (United States) Cancer Causes Control, 3: 7–14, 2002

  6. Auer GU, Fallenius AG, Erhardt KY, Sundelin BS: Progression of mammary adenocarcinomas as reflected by nuclear DNA content. Cytometry 5: 420–425, 1984

    Google Scholar 

  7. Pallis L, Skoog L, Falkmer U, Wilking N, Rutquist LE, Auer G, Cedermark B: The DNA profile of breast cancer in situ. Eur J Surg Oncol 18: 108–111, 1992

    Google Scholar 

  8. Iglehart JD, Kerns BJ, Huper G, Marks JR: Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat 34: 253–263, 1995

    Google Scholar 

  9. Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R: Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 69: 1174–1181, 1992

    Google Scholar 

  10. Robertson JF: Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 73: 5–12, 1996

    Google Scholar 

  11. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 406: 747–752, 2000

    Google Scholar 

  12. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869–10874, 2001

    Google Scholar 

  13. AndersonWF, Chu KC, Chatterjee N, Brawley O, Brinton LA: Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the Surveillance, Epidemiology, and End Results database. J Clin Oncol 19: 18–27, 2001

    Google Scholar 

  14. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW: Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 92: 37–45, 2001

    Google Scholar 

  15. Simpson JF, Page DL: Status of breast cancer prognostication based on histopathologic data. Am J Clin Pathol 102: S3–S8, 1994

    Google Scholar 

  16. Percy C, Holten VV, Muir C (eds): International Classifi-cation of Diseases for Oncology. World Health Organization, Geneva, 199

  17. Kleinbaum DG, Kupper LL, Morgenstern H: Epidemiologic Research: Principles and Quantitative Methods. John Wiley & Sons, New York,1982

    Google Scholar 

  18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958

    Google Scholar 

  19. Peto R, Peto J: Asymptomatically efficient rank invariant test procedures. J R Stat Soc A 135: 185–198, 1972

    Google Scholar 

  20. Cox DR: Regression models and life-tables. J R Stat Soc B 34: 187–220, 1972

    Google Scholar 

  21. Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2: 1102–1109, 1984

    Google Scholar 

  22. Clemmesen J: Carcinoma of the breast. Br J Radiol 21: 583–590, 1948

    Google Scholar 

  23. Anderson E: Possible relationship between menopause and age at onset of breast cancer. Cancer 3: 141–410, 1950

    Google Scholar 

  24. Brinton LA, Benichou J, Gammon MD, Brogan DR, Coates R, Schoenberg JB: Ethnicity and variation in breast cancer incidence. Int J Cancer 73: 349–355, 1997

    Google Scholar 

  25. Velentgas P, Daling JR: Risk factors for breast cancer in younger women. J. Natl Cancer Inst Monogr 16: 15–24, 1994

    Google Scholar 

  26. Edwards MJ, Gamel JW, Vaughan WP, Wrightson WF: Infiltrating ductal carcinoma of the breast: the survival impact of race. J Clin Oncol 16: 2693–2699, 1998

    Google Scholar 

  27. Yasui Y, Potter JD: The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 10: 431–437, 1999

    Google Scholar 

  28. Armitage P, Doll R: A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer 11: 161–169, 19

    Google Scholar 

  29. Armitage P, Doll R: The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 8: 1–12, 1954

    Google Scholar 

  30. Lilienfeld AM, Johnson EA: The age distribution in female breast and genital cancers. Cancer 8: 875–882, 1955

    Google Scholar 

  31. Peto J, Mack TM: High constant incidence in twins and other relatives of women with breast cancer [In Process Citation]. Nat Genet 26: 411–414, 2000

    Google Scholar 

  32. Bertram JS: The molecular biology of cancer. Mol Aspects Med 21: 167–223, 2000

    Google Scholar 

  33. Loeb LA: A mutator phenotype in cancer. Cancer Res 61: 3230–3239, 2001

    Google Scholar 

  34. Nandi S, Guzman RC, Yang J: Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92: 3650–3657, 1995

    Google Scholar 

  35. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, FriedrichsWE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC: A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 60: 4026–4029, 2000

    Google Scholar 

  36. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, CroninWM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388, 1998

    Google Scholar 

  37. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286: 2251–2556, 2001

    Google Scholar 

  38. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case–control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356: 1876–1881, 2000

    Google Scholar 

  39. Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes [see comments]. Cancer 83: 310–319, 1998

    Google Scholar 

  40. Phillips KA: Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18: 107S–112S, 2000

    Google Scholar 

  41. Jordan VC, Allen KE: Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16: 239–251, 19

    Google Scholar 

  42. Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12: 419–424, 1976

    Google Scholar 

  43. Early breast cancer trialist's collaborative group. Systemic Treatment of Early Breast Cancer by Hormonal, Cytotoxic, or Immune Therapy. 133 Randomized Trials Involving 31,000 Recurrences and 24,000 Death Among 75,000 Women, pp. 1–15, 71–85, 199

  44. Buchanan RB, Blamey RW, Durrant KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4: 1326–1330, 1986

    Google Scholar 

  45. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91: 1475–1479, 19

    Google Scholar 

  46. Peto J, Houlston RS: Genetics and the common cancers. Eur J Cancer 37(Suppl 8): 88–96, 2001

    Google Scholar 

  47. Frey CM, McMillen MM, Cowan CD, Horm JW, Kessler LG: Representativeness of the surveillance, epidemiology, and end results program data: recent trends in cancer mortality rates. J Natl Cancer Inst 84: 872–877, 1992

    Google Scholar 

  48. De Waard F: Premenopausal and postmenopausal breast cancer: one disease or two? J Natl Cancer Inst 63: 549–552, 1979

    Google Scholar 

  49. De Waard F, Baanders-van Halewijn EA, Huizinga J: The bimodal age distribution of patients with mammary carcinoma. Cancer 17: 141–151, 1963

    Google Scholar 

  50. De Waard F, De Laive JWJ, Baanders-van Halewijn EA: On bimodal age distribution of mammary carcinoma. Br J Cancer 14: 437–448, 19

    Google Scholar 

  51. von Pirquet C. Allergie des Lebensalters, die bosartigen Geschwulste (Allergy of age, the Malignant Tumors), Thieme Verlag, Leipzig, Germany, 1930

  52. Muguti GI: Experience with breast cancer in Zimbabwe. J R Coll Surg Edinburgh 38: 75–78, 1993

    Google Scholar 

  53. Chie WC, Chen CF, Lee WC, Chen CJ, Lin RS: Age-periodcohort analysis of breast cancer mortality. Anticancer Res 15: 511–515, 1995

    Google Scholar 

  54. Sant M, Gatta G, Micheli A, Verdecchia A, Capocaccia R, Crosignani P, Berrino F: Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer 27: 981–984, 1991

    Google Scholar 

  55. Clemmesen J, Busk T: Cancer mortality among men and women in Denmark, England, and Switzerland. V. Incidence of accessible and inaccessible cancers in Danish towns and rural areas. Cancer Res 9: 415–421, 1949

    Google Scholar 

  56. Moolgavkar SH, Lee JA, Hade RD: Comparison of agespecific mortality from breast cancer in males in the United States and Japan. J Natl Cancer Inst 60: 1223–1225, 1978

    Google Scholar 

  57. Thomas DB: Breast cancer in men. Epidemiol Rev 15: 220–231, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anderson, W.F., Chatterjee, N., Ershler, W.B. et al. Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database. Breast Cancer Res Treat 76, 27–36 (2002). https://doi.org/10.1023/A:1020299707510

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020299707510

Navigation